Moderna is defending its COVID-19 vaccine after a study found an increase in reports of myocarditis, which is an inflammation of the heart, in males ages 12 to 29 — about 13.3 cases in every 100,000 subjects. The pharmaceutical giant said the benefits of the vaccine outweigh the risk of the possible negative side effect.
